$ASPI
ASP Isotopes Inc.

2022 Q4 Form 10-Q Financial Statement

#000121390022082183 Filed on December 22, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.377M $1.208M $570.0K
YoY Change
% of Gross Profit
Research & Development $94.44K $745.5K $293.1K
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.472M $1.954M $858.3K
YoY Change 284.42%
Operating Profit -$1.954M -$858.3K
YoY Change 284.42%
Interest Expense $1.480K $450.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $166.2K -$2.900K $665.00
YoY Change
Pretax Income -$1.304M -$1.956M -$860.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.304M -$1.956M -$857.6K
YoY Change 284.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.03
Diluted Earnings Per Share -$0.06 -$0.06 -$0.03
COMMON SHARES
Basic Shares Outstanding 34.36M shares 30.11M shares
Diluted Shares Outstanding 30.11M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.389M $431.6K
YoY Change
Cash & Equivalents $2.389M $431.6K $3.771M
Short-Term Investments
Other Short-Term Assets $913.0K $1.153M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.302M $1.584M
YoY Change 2.51%
LONG-TERM ASSETS
Property, Plant & Equipment $8.201M $7.766M
YoY Change 174.43%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $139.6K $131.4K
YoY Change
Total Long-Term Assets $9.194M $7.897M
YoY Change 134.46%
TOTAL ASSETS
Total Short-Term Assets $3.302M $1.584M
Total Long-Term Assets $9.194M $7.897M
Total Assets $12.50M $9.481M
YoY Change 74.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.355M $1.156M
YoY Change 2170.32%
Accrued Expenses $361.2K $1.018M
YoY Change 749.99%
Deferred Revenue
YoY Change
Short-Term Debt $33.85K $33.85K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.936M $2.452M
YoY Change 538.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $742.4K $710.8K
YoY Change
Total Long-Term Liabilities $742.4K $710.8K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.936M $2.452M
Total Long-Term Liabilities $742.4K $710.8K
Total Liabilities $2.679M $3.163M
YoY Change 133.96%
SHAREHOLDERS EQUITY
Retained Earnings -$7.553M -$6.249M
YoY Change 189.62%
Common Stock $359.1K $301.1K
YoY Change 73.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.817M $6.318M $7.022M
YoY Change
Total Liabilities & Shareholders Equity $12.50M $9.481M
YoY Change 74.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.304M -$1.956M -$857.6K
YoY Change 284.9%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$862.0K -$694.3K -$287.9K
YoY Change 2048.9%
INVESTING ACTIVITIES
Capital Expenditures $902.5K $1.838M $898.9K
YoY Change 839.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$902.5K -$1.838M -$898.9K
YoY Change 839.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.790M 0.000 $2.233M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -862.0K -694.3K -$287.9K
Cash From Investing Activities -902.5K -1.838M -$898.9K
Cash From Financing Activities 3.790M 0.000 $2.233M
Net Change In Cash 2.026M -2.532M $1.046M
YoY Change -233.71%
FREE CASH FLOW
Cash From Operating Activities -$862.0K -$694.3K -$287.9K
Capital Expenditures $902.5K $1.838M $898.9K
Free Cash Flow -$1.765M -$2.532M -$1.187M
YoY Change 1010.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41555
dei Entity Registrant Name
EntityRegistrantName
ASP Isotopes Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2618235
dei Entity Address Address Line1
EntityAddressAddressLine1
433 Plaza Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
dei City Area Code
CityAreaCode
(561)
dei Local Phone Number
LocalPhoneNumber
709-3034
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
ASPI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34357127 shares
CY2022Q3 us-gaap Cash
Cash
431565 usd
CY2021Q4 us-gaap Cash
Cash
2953721 usd
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
547373 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
605174 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
267562 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
1584112 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
3221283 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6891721 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2988210 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
873997 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
933145 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131408 usd
CY2022Q3 us-gaap Assets
Assets
9481238 usd
CY2021Q4 us-gaap Assets
Assets
7142638 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1156253 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
59679 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
977539 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42500 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
33854 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
46900 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40667 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38072 usd
CY2022Q3 aspi Fair Value Of Shares Issuable
FairValueOfSharesIssuable
243885 usd
CY2021Q4 aspi Fair Value Of Shares Issuable
FairValueOfSharesIssuable
116200 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2452198 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
303351 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
710821 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
841623 usd
CY2022Q3 us-gaap Liabilities
Liabilities
3163019 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1144974 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30107127 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30107127 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20652500 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20652500 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
301071 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
206525 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11971568 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8380343 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6248915 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2607927 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
294495 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18723 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6318219 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5997664 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9481238 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7142638 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
745461 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1191901 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1208319 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
508247 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2448091 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1953780 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
508247 usd
us-gaap Operating Expenses
OperatingExpenses
3639992 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1953780 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-508247 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3639992 usd
CY2022Q3 aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
-2903 usd
aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
-2903 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
453 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1907 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2450 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-996 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1956230 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-508247 usd
us-gaap Net Income Loss
NetIncomeLoss
-3640988 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30107127 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2844444 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28642533 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1956230 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-508247 usd
us-gaap Net Income Loss
NetIncomeLoss
-3640988 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
150501 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-11076 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
275772 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1805729 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-519323 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3365216 usd
CY2021Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
500000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2075000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-11076 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-508247 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2055677 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5997664 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
285024 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2090186 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20803 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-229257 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-857588 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7021808 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
95723 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
648627 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
210745 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
354528 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-827170 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7408538 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
715410 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
150501 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1956230 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6318219 usd
us-gaap Net Income Loss
NetIncomeLoss
-3640988 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-508247 usd
us-gaap Share Based Compensation
ShareBasedCompensation
946958 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
500000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-2903 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
51624 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-547373 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
337612 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
131408 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
763695 usd
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-24063 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
935039 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-120697 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2077859 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32310 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3570632 usd
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195712 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3570632 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-195712 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3119560 usd
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2075000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
255965 usd
CY2021Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
46900 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13046 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2850549 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2121900 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2797942 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1893878 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275786 usd
CY2021Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11077 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953721 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
431565 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1882801 usd
us-gaap Stock Issued1
StockIssued1
124782 usd
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
332879 usd
CY2022Q4 us-gaap Share Price
SharePrice
4
CY2022Q4 us-gaap Shares Issued
SharesIssued
187500 shares
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3700000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1956230 usd
us-gaap Net Income Loss
NetIncomeLoss
-3640988 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-508247 usd
CY2022Q3 us-gaap Cash
Cash
431565 usd
aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
116200 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
116200 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
124782 usd
us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
2903 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation and Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk and other Risks</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
CY2022Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
243885 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
243885 usd
CY2016Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12Y
CY2022Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P12Y
CY2022Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6891721 usd
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2988210 usd
us-gaap Commitments To Complete Contracts In Process
CommitmentsToCompleteContractsInProcess
$6,800,000
CY2022Q3 us-gaap Other Commitment
OtherCommitment
5972000 usd
CY2021Q4 us-gaap Other Commitment
OtherCommitment
1800000 usd
CY2021Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.075 pure
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
952521 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
952521 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
873997 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40667 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
710821 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
32452 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
97357 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
20585 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
71343 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075 pure
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075 pure
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2022Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.075 pure
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.075 pure
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
23484 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
97460 usd
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
104770 usd
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
112627 usd
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
121074 usd
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
582175 usd
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1041590 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
290102 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
751488 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40667 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
710821 usd
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
100000 usd
CY2022Q1 aspi Royalty Percentage On Sale Of Products
RoyaltyPercentageOnSaleOfProducts
0.10 pure
CY2022Q3 us-gaap Notes Payable
NotesPayable
400000 usd
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000000 zar
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30107127 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30107127 shares
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15100000 shares
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.25
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1452500 shares
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2
CY2021Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
226000 usd
CY2021Q4 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
58100 shares
CY2022Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
255965 usd
us-gaap Stock Issued During Period Shares Dividend Reinvestment Plan
StockIssuedDuringPeriodSharesDividendReinvestmentPlan
62391 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.765 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0021 pure
aspi Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P2Y
aspi Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate
0 pure
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6000000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
400000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.25
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
700000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2751000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
250000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2901000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
aspi Weighted Average Remaining Contractual Term
WeightedAverageRemainingContractualTerm
P9Y7M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6818760 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
221386 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
1.64
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P9Y6M
aspi Aggregate Intrinsic Value Exercisable
AggregateIntrinsicValueExercisable
580540 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2901000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.91
aspi Weighted Average Remaining Contractual Termin Years Vested Or Expected To Vest
WeightedAverageRemainingContractualTerminYearsVestedOrExpectedToVest
P9Y7M6D
aspi Aggregate Intrinsic Value Vested Or Expected To Vest
AggregateIntrinsicValueVestedOrExpectedToVest
6818760 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2100000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
700000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2800000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
715410 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
500000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
946958 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
1956230 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
508247 usd
us-gaap Profit Loss
ProfitLoss
3640988 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
30107127 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2844444 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
28642533 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2021Q3 aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28642533 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30107127 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2844444 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2021Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
usd
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
usd
CY2021Q3 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
usd
CY2021Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
usd
CY2021Q3 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
usd
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
CY2021Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2021Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2021Q3 us-gaap Stock Issued1
StockIssued1
usd
CY2021Q3 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
usd
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
usd
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28642533 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30107127 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2844444 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
dei Entity Central Index Key
EntityCentralIndexKey
0001921865

Files In Submission

Name View Source Status
0001213900-22-082183-index-headers.html Edgar Link pending
0001213900-22-082183-index.html Edgar Link pending
0001213900-22-082183.txt Edgar Link pending
0001213900-22-082183-xbrl.zip Edgar Link pending
aspi-20220930.xsd Edgar Link pending
f10q0922ex31-1_aspisotopes.htm Edgar Link pending
f10q0922ex31-2_aspisotopes.htm Edgar Link pending
f10q0922ex32-1_aspisotopes.htm Edgar Link pending
f10q0922ex32-2_aspisotopes.htm Edgar Link pending
f10q0922_aspisotopes.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
aspi-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aspi-20220930_pre.xml Edgar Link unprocessable
aspi-20220930_lab.xml Edgar Link unprocessable
aspi-20220930_def.xml Edgar Link unprocessable
f10q0922_aspisotopes_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending